Koji Azuma
Overview
Explore the profile of Koji Azuma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
146
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ando S, Futami S, Azuma K, Nishimatsu K, Shirasaka T, Minami S
J Med Cases
. 2024 Aug;
15(8):153-158.
PMID: 39091578
Various driver mutations and the corresponding molecular-targeted drugs have been detected and developed in non-small cell lung cancer. There were many cases in which surgical specimens had happened to find...
2.
Ando S, Azuma K, Futami S, Mori K, Hirose Y, Shirasaka T, et al.
J Med Cases
. 2024 Jul;
15(7):120-125.
PMID: 38993806
Kampo medicine, a traditional Japanese herbal medicine, is covered by the Japanese National Health Insurance and prescribed for various purposes. While relatively safe with few adverse effects, it may potentially...
3.
Naito M, Fukushima K, Kusakabe S, Endo T, Shiroyama T, Ohira K, et al.
BMC Infect Dis
. 2023 Aug;
23(1):517.
PMID: 37550642
Background: Mycobacterium obuense (M. obuense) is a rapidly growing mycobacterium (RGM) which has been considered nonpathogenic. Here, we report a case of disseminated non-tuberculous mycobacterial (NTM) infection caused by M....
4.
Correction to: Nivolumab treatment beyond progressive disease in advanced non‑small cell lung cancer
Enomoto T, Tamiya A, Matsumoto K, Adachi Y, Azuma K, Inagaki Y, et al.
Clin Transl Oncol
. 2022 Feb;
24(7):1445.
PMID: 35192137
No abstract available.
5.
Enomoto T, Inoue Y, Adachi Y, Kouno S, Inagaki Y, Azuma K, et al.
Turk Thorac J
. 2022 Feb;
22(3):212-216.
PMID: 35110230
Objective: This study evaluated the relationship between end-tidal carbon dioxide (EtCO2) measured with a portable capnometer and PaCO2 in respiratory disease patients. Material And Methods: We retrospectively reviewed patients whose...
6.
Murakami Y, Tamiya A, Taniguchi Y, Adachi Y, Enomoto T, Azuma K, et al.
Thorac Cancer
. 2022 Jan;
13(4):593-601.
PMID: 34989133
Background: Nivolumab, an immune checkpoint inhibitor (ICI), has changed the treatment paradigm for advanced non-small cell lung cancer (NSCLC). However, factors associated with long-term survival in NSCLC patients treated with...
7.
Azuma K, Takimoto T, Kasai T, Hirose M, Hatsuda K, Sugimoto C, et al.
Respir Investig
. 2021 May;
59(6):757-765.
PMID: 33967014
Background: Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease characterized by the abnormal accumulation of surfactant-like material within the alveolar spaces and distal bronchioles. If high-resolution computed tomography (HRCT)...
8.
Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, et al.
Eur J Cancer
. 2021 Jan;
145:183-193.
PMID: 33486442
Background: The data of sequential therapy of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in clinical practice have been limited. Methods: We reviewed the clinical data of patients with...
9.
Enomoto T, Tamiya A, Matsumoto K, Adachi Y, Azuma K, Inagaki Y, et al.
Clin Transl Oncol
. 2020 Jul;
23(3):582-590.
PMID: 32661824
Purpose: This study evaluated the efficacy and safety of nivolumab treatment beyond progressive disease (PD) in non-small cell lung cancer (NSCLC). Patients/methods: Medical records of consecutive patients with advanced NSCLC...
10.
Hasegawa Y, Ikuta R, Matsuda N, Tamaki K, Lo H, Yamamoto T, et al.
Nat Commun
. 2019 Jan;
10(1):378.
PMID: 30692532
An all-optical network is identified as a promising infrastructure for fast and energy-efficient communication. Recently, it has been shown that its quantum version based on 'all-photonic quantum repeaters'-inheriting, at least,...